Last edition
News about "Evergreen Theragnostics"
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of USD 250 Million
The addition of Evergreen’s scalable manufacturing capabilities and infrastructure enhances Lantheus’ ability to meet the complex demands of radiopharmaceutical development and production.
Evergreen Theragnostics | 29/01/2025 | By Aishwarya
The expanded collaboration will leverage Orbit Discovery’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen Theragnostics’ expertise in radiopharmaceutical development and clinical translation.
Evergreen Theragnostics | 04/12/2024 | By Aishwarya
Evergreen Theragnostics Opens Phase II Small Cell Lung Cancer Clinical Trial in EU
The CCK2-VIEW trial uses 68Ga-EVG321, a peptide-based Radioligand imaging agent administered to patients with small cell lung cancer.
Evergreen Theragnostics | 18/10/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy